{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:10:46Z","timestamp":1759731046772,"version":"3.37.3"},"reference-count":24,"publisher":"FapUNIFESP (SciELO)","issue":"4","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT Background: Real-world data on the use of Ustekinumab (UST) in Brazilian and Latin American patients with Crohn\u2019s disease (CD) are scarce. Objective: The primary endpoint was assessment of clinical remission at weeks 8 and 52, and secondary endpoints were: assessment of clinical response at weeks 8 and 52, endoscopic remission, adverse events, and rates of CD-related abdominal surgery during follow-up. Methods: observational and retrospective study, including patients with CD treated at two centers, who received UST at any time during their treatment. Remission and clinical response were defined as a Harvey-Bradshaw index \u22644 and \u22653 points reduction, respectively. Results: Seventy-four patients were included, 85.1% previously exposed to anti-TNFs. Clinical remission was observed in 45.8% and 59.4% of patients at weeks 8 and 52, respectively. The clinical response rates were 54.2% and 67.6% at weeks 8 and 52. Endoscopic remission was observed in 21.8% of patients. Seventeen patients had adverse events, mostly mild infections, with 22.9% of patients undergoing abdominal surgery (ileocolectomy being the most common procedure). Conclusion UST therapy resulted in significant rates of remission and clinical response, as described in other real-world studies. Few patients had adverse events during treatment, showing its adequate safety profile.<\/jats:p>","DOI":"10.1590\/s0004-2803.202204000-89","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T15:22:07Z","timestamp":1668439327000},"page":"501-507","source":"Crossref","is-referenced-by-count":2,"title":["USTEKINUMAB IN CROHN\u2019S DISEASE MANAGEMENT: A BRAZILIAN OBSERVATIONAL STUDY"],"prefix":"10.1590","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8609-0486","authenticated-orcid":false,"given":"Paula Cenira Senger de","family":"CASTRO","sequence":"first","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8180-6254","authenticated-orcid":false,"given":"Dani\u00e9la Oliveira","family":"MAGRO","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6256-2629","authenticated-orcid":false,"given":"Rodrigo Bremer","family":"NONES","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9516-0378","authenticated-orcid":false,"given":"Thaisa Kowalski","family":"FURLAN","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4011-5112","authenticated-orcid":false,"given":"Eron F\u00e1bio","family":"MIRANDA","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9632-6691","authenticated-orcid":false,"given":"Paulo Gustavo","family":"KOTZE","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2022,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn\u2019s disease","volume":"380","author":"Baumgart DC","year":"2012","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/MOG.0000000000000534","article-title":"The globalization of inflammatory bowel disease: The incidence and prevalence of inflammatory bowel disease in Brazil","volume":"35","author":"Quaresma AB","year":"2019","journal-title":"Curr Opin Gastroenterol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","article-title":"Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with Inflammatory bowel diseases: A systematic review and meta-analysis","volume":"12","author":"Singh S","year":"2018","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan BG","year":"2016","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/JIR.S157358","article-title":"Clinical utility of ustekinumab in crohn\u2019s disease","volume":"11","author":"Kotze PG","year":"2018","journal-title":"J Inflamm Res"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/apt.14016","article-title":"Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn\u2019s disease: real world experience from a multicentre cohort","volume":"45","author":"Ma C","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/apt.14487","article-title":"Long-term efficacy and safety of ustekinumab in 122 refractory Crohn\u2019s disease patients: a multicentre experience","volume":"47","author":"Wils P","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg MS","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/gast.2002.31072","article-title":"A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn\u2019s disease","volume":"122","author":"Sandborn WJ","year":"2002","journal-title":"Gastroenterology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0140-6736(80)92858-5","article-title":"A Simple Index Of Crohn\u2019s-Disease Activity","volume":"315","author":"Harvey R","year":"1980","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.cgh.2010.01.001","article-title":"Correlation Between the Crohn\u2019s Disease Activity and Harvey-Bradshaw Indices in Assessing Crohn\u2019s Disease Severity","volume":"8","author":"Vermeire S","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/apt.15958","article-title":"Real-world long-term effectiveness of ustekinumab in Crohn\u2019s disease: results from the ENEIDA registry","volume":"52","author":"Iborra M","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/apt.15371","article-title":"Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn\u2019s disease: results from the ENEIDA registry","volume":"50","author":"Iborra M","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"ref14","first-page":"272","article-title":"Ustekinumab in Crohn\u2019s disease: real-world outcomes and predictors of response","volume":"114","author":"Lorenzo Gonz\u00e1lez L","year":"2022","journal-title":"Rev Espa\u00f1ola Enfermedades Dig"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ecco-jcc\/jjz119","article-title":"Ustekinumab for Crohn\u2019s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study","volume":"14","author":"Biemans VBC","year":"2020","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/ecco-jcc\/jjz080","article-title":"Long-term clinical effectiveness of ustekinumab in patients with Crohn\u2019s disease who failed biologic therapies: A national cohort study","volume":"13","author":"Liefferinckx C","year":"2019","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.3390\/jcm8122140","article-title":"Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn\u2019s Disease: Real-World Data from a German IBD Cohort","volume":"8","author":"Kubesch A","year":"2019","journal-title":"J Clin Med"},{"key":"ref18","first-page":"8","article-title":"A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease","volume":"2","author":"Bennett A","year":"2020","journal-title":"Crohn\u2019s Colitis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.dld.2019.05.002","article-title":"Effectiveness and safety of Ustekinumab for Crohn\u2019s disease; systematic review and pooled analysis of real-world evidence","volume":"51","author":"Engel T","year":"2019","journal-title":"Dig Liver Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000503959","article-title":"Efficacies and Related Issues of Ustekinumab in Japanese Patients with Crohn\u2019s Disease: A Preliminary Study","volume":"101","author":"Miyazaki T","year":"2020","journal-title":"Digestion"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/ecco-jcc\/jjaa177","article-title":"Effectiveness and safety of Ustekinumab intensification at 90mg every four weeks in Crohns disease: a multicenter study","volume":"15","author":"Fumery M","year":"2020","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cgh.2020.02.035","article-title":"Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn\u2019s Disease","volume":"19","author":"Ollech JE","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.crohns.2014.06.005","article-title":"Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn\u2019s disease-The McGill experience","volume":"8","author":"Kopylov U","year":"2014","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1007\/s12325-020-01276-3","article-title":"Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn\u2019s Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States","volume":"37","author":"Obando C","year":"2020","journal-title":"Adv Ther"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":["Ustequinumabe no manejo da doen\u00e7a de Crohn: um estudo observacional brasileiro"],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0004-28032022000400501&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T20:10:46Z","timestamp":1701375046000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032022000400501&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["S0004-28032022000400501"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.202204000-89","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"type":"electronic","value":"1678-4219"},{"type":"print","value":"0004-2803"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}